Am­plyx grabs $67M to fund a piv­otal dri­ve to the FDA with an an­ti-fun­gal aimed at a lethal threat

Am­plyx Plar­ma­ceu­ti­cals is prep­ping a move in­to a piv­otal Phase II pro­gram for its an­ti-fun­gal drug with a siz­able $67 mil­lion round in hand to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.